Verra Mobility Securities Fraud Class Action Filed After CEO OusterJuly 1, 2026Law and PolicyA securities fraud class action filed June 13, 2026, targets Verra Mobility after its board terminated the CEO, triggering a stock drop and an August 4 lead plaintiff deadline.
Securities Fraud Class Action Targets GeneDx Over Fabric Genomics DealJuly 1, 2026Law and PolicyA federal securities fraud class action targets GeneDx Holdings over a $31.3 million impairment tied to the Fabric Genomics acquisition, following a 49% stock drop.
Securities Fraud Class Action Targets GeneDx Holdings Over WGS Stock LossesJuly 1, 2026Law and PolicyKessler Topaz filed a securities fraud class action against GeneDx Holdings in Connecticut federal court, covering WGS investors from April 2025 to May 2026.
Zoetis Faces Securities Fraud Class Action Over Drug Adoption ClaimsJune 19, 2026Law and PolicyA securities fraud class action filed against Zoetis Inc. targets investor disclosures about product adoption, with a lead plaintiff deadline of July 27, 2026.
Zoetis Faces Securities Fraud Class Action Over Product Adoption ClaimsJune 18, 2026Law and PolicyA securities fraud class action filed June 17, 2026, targets Zoetis Inc. over alleged misstatements about product adoption rates, with a July 27 lead plaintiff deadline.
Verra Mobility Faces Securities Fraud Class Action After CEO TerminationJune 18, 2026Law and PolicyKessler Topaz filed a securities fraud class action against Verra Mobility in Arizona federal court, citing alleged misstatements about commercial growth and a CEO termination.
Sportradar Securities Fraud Class Action Filed Over Illegal Gambling TiesMay 22, 2026Law and PolicyA securities fraud class action filed May 20, 2026, alleges Sportradar concealed its ties to illegal gambling operators, exposing investors to undisclosed regulatory risk.
Gemini Space Station Faces Securities Fraud Class Action Over IPO DisclosuresMay 20, 2026Law and PolicyA securities fraud class action filed May 2, 2026, in the SDNY targets Gemini Space Station over alleged IPO misstatements, with shares down 78.7% from their offering price.
ImmunityBio Securities Fraud Class Action Targets Cancer Drug ClaimsMay 16, 2026Law and PolicyA securities fraud class action filed May 11 targets ImmunityBio and CEO Patrick Soon-Shiong over alleged false claims that cancer drug Anktiva was a vaccine.
ImmunityBio Faces Securities Fraud Class Action Over Two-Month Trading WindowMay 8, 2026Law and PolicyA securities fraud class action filed against ImmunityBio Inc. in the Central District of California covers a narrow two-month trading window, with a lead plaintiff deadline of May 26, 2026.